CAM
NERV icon

Cormorant Asset Management’s Minerva Neurosciences NERV Stock Holding History

Cormorant Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,968
Closed -$167K – 84
2021
Q3 		$167K Sell
11,968
-18,750
-61% -$282K 0.01% 87
2021
Q2 		$570K Buy
30,718
+5,718
+23% +$123K 0.02% 100
2021
Q1 		$584K Hold
25,000
– – 0.01% 116
2020
Q4 		$468K Sell
25,000
-4,852
-16% -$122K 0.01% 105
2020
Q3 		$759K Sell
29,852
-34,168
-53% -$924K 0.03% 91
2020
Q2 		$1.85M Sell
64,020
-11,968
-16% -$702K 0.07% 77
2020
Q1 		$3.66M Hold
75,988
– – 0.17% 61
2019
Q4 		$4.32M Hold
75,988
– – 0.17% 62
2019
Q3 		$4.71M Hold
75,988
– – 0.29% 56
2019
Q2 		$3.42M Hold
75,988
– – 0.2% 63
2019
Q1 		$4.78M Hold
75,988
– – 0.32% 50
2018
Q4 		$4.1M Hold
75,988
– – 0.33% 54
2018
Q3 		$7.63M Hold
75,988
– – 0.5% 42
2018
Q2 		$5.01M Hold
75,988
– – 0.37% 49
2018
Q1 		$3.8M Hold
75,988
– – 0.28% 44
2017
Q4 		$3.68M Hold
75,988
– – 0.39% 43
2017
Q3 		$4.62M Sell
75,988
-173,689
-70% -$9.96M 0.82% 35
2017
Q2 		$17.7M Sell
249,677
-38,811
-13% -$2.51M 2.93% 14
2017
Q1 		$18.7M Sell
288,488
-43,067
-13% -$3.34M 2.71% 12
2016
Q4 		$31.2M Sell
331,555
-18,445
-5% -$1.88M 4.2% 6
2016
Q3 		$39.5M Hold
350,000
– – 4.36% 4
2016
Q2 		$28.6M Buy
350,000
+130,882
+60% +$8.32M 4.05% 6
2016
Q1 		$10.8M Buy
219,118
+75,988
+53% +$3.24M 1.62% 24
2015
Q4 		$6.95M Hold
143,130
– – 0.83% 40
2015
Q3 		$6.01M Sell
143,130
-2
-0% -$92 0.96% 33
2015
Q2 		$6.64M Buy
143,132
+2
+0% +$85 0.88% 34
2015
Q1 		$5.72M Buy
143,130
+121,255
+554% +$5.02M 0.88% 39
2014
Q4 		$1.05M Hold
21,875
– – 0.16% 61
2014
Q3 		$1.06M Buy
+21,875
New +$1.16M 0.22% 60

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Cormorant Asset Management's NERV Position: Q4 2021 in Review

Cormorant Asset Management sold out of Minerva Neurosciences (NERV) in Q4 2021, closing a stake of 11,968 shares — an estimated $167K sold.

Cormorant Asset Management first reported a position in NERV in Q3 2014 and held it in 29 quarters. The position peaked at $39.5M in Q3 2016. 35 funds tracked by Wall St. Rank hold NERV as of Q4 2021.

  • Cormorant Asset Management reported no remaining Minerva Neurosciences position as of Q4 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 11,968 Minerva Neurosciences shares in Q4 2021, an estimated $167K.
  • Cormorant Asset Management first reported a position in Minerva Neurosciences in Q3 2014 and held it in 29 quarters.
  • Cormorant Asset Management's Minerva Neurosciences position peaked at $39.5M in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2021.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.